- Companies
- Truvian Sciences
Truvian Sciences Funding, Investors & Competitors
Truvian Sciences has raised $208M across 4 funding rounds, most recently a $74M Series D in July 2024.
Last Truvian Sciences funding round
$74M
Series D · Jul 2024
Cumulative funding Truvian Sciences raised
$208M
across 4 funding rounds
Key investors in Truvian Sciences
GreatPoint Ventures
DNS Capital
Tao Capital Partners
7wire Ventures
Wittington Ventures
TYH Ventures
General Catalyst
Domain Associates
About Truvian Sciences
Truvian Sciences is a San Diego-based diagnostics company, founded in 2015, that develops an automated benchtop blood-testing system consolidating multiple routine tests, including complete blood count, metabolic panel, lipid panel, kidney function, cholesterol, and glucose levels, into a single device using one blood sample. The platform is designed for point-of-care settings such as retail clinics, pharmacies, physician offices, and corporate clinics, pairing lab-accurate results with software for sharing test data with patients. Truvian aims to decentralize routine diagnostic testing away from traditional central laboratories.
Founded
2015
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Product sales
Truvian Sciences Funding History
Truvian Sciences has raised a total of $208M across 4 funding rounds.
Truvian Sciences' first fundraising round was a $2M seed round in September 2015. The most recent completed round was a $74M Series D in July 2024.
Truvian Sciences funding rounds
| Date | Stage | Investors | Raised | Deal Summary |
|---|---|---|---|---|
| Jul 2024 | Series D | GreatPoint Ventures (lead); Wittington Ventures (lead); DNS Capital; Tao Capital Partners; 7wire Ventures; TYH Ventures; Medical Excellence Capital | $74M | Truvian Sciences raised $74 million in a Series D funding round on July 17, 2024, led by GreatPoint Ventures and Wittington Ventures, with participation from 7wire Ventures, DNS Capital, Medical Excellence Capital, Tao Capital Partners, and TYH Ventures. This brought the company's total funding to approximately $224.1 million to $294 million across seven rounds. The funds were used to pursue initial FDA clearance for its blood-testing platform. Truvian Sciences develops a blood-testing technology platform aimed at providing faster, more accessible diagnostic results compared to traditional lab methods. The company operates in the biotech sector, focusing on point-of-care diagnostics to measure key health biomarkers from a small blood sample. |
| Feb 2021 | Series C | 7wire Ventures (lead); TYH Ventures (lead); Wittington Ventures (lead); General Catalyst; DNS Capital; GreatPoint Ventures; Synetro Group; Wasson Enterprise; Pioneer Healthcare Partners | $105M | Truvian Sciences, a San Diego-based diagnostics company founded in 2015, develops an automated benchtop blood testing system that consolidates multiple routine tests such as complete blood count, metabolic panel, lipid panel, kidney function, cholesterol, and glucose levels into a single device using one sample, aiming to enable point-of-care testing in settings like retail clinics, pharmacies, physician offices, and corporate clinics. The platform seeks to decentralize healthcare by providing lab-accurate results quickly, with an accompanying software tool for sharing test data with patients. On February 24, 2021, Truvian closed an oversubscribed Series C financing round raising more than $105 million, led by TYH Ventures, Glen Tullman of 7wireVentures, and Wittington Ventures, with participation from DNS Capital, General Catalyst, GreatPoint Ventures, Pioneer Healthcare Partners, Synetro Group, Wasson Enterprise, and others. The funding will support FDA 510(k) clearance and CLIA waiver submissions planned before year-end 2021, ramp up clinical trials, scale manufacturing of test cartridges, and double the team from 87 employees, including a recent hire from Abbott. New board members include Glen Tullman (former Livongo CEO), Greg Wasson (former Walgreens Boots Alliance CEO), and Megh Gupta (Wittington Ventures). CEO Jeff Hawkins highlighted the pandemic's role in accelerating demand for convenient, consumer-directed diagnostics. Truvian's technology draws from large reference lab capabilities miniaturized for point-of-care use, positioning it amid heightened investor interest in diagnostics post-COVID, with targets like CVS, Walgreens, One Medical, and Crossover Health. The company had previously raised funds in earlier rounds, with total funding reaching over $224 million across seven rounds by 2024, including a $74 million Series D in July 2024 led by similar investors. |
| Nov 2019 | Series B | GreatPoint Ventures (lead); DNS Capital; Tao Capital Partners; Domain Associates | $27M | Truvian Sciences is developing an automated benchtop blood testing system that delivers lab-accurate results in 20 minutes for a full suite of health tests from a small blood sample, aiming to provide a convenient, affordable alternative to off-site labs. On November 20, 2019, the company closed a $27.1 million Series B financing round led by GreatPoint Ventures, with participation from DNS Capital, Tao Capital Partners, and existing investor Domain Associates, bringing total funding to $46.3 million. The funds were intended to accelerate development toward an FDA submission planned for 2020. Jeff Hawkins, President and CEO, highlighted Truvian's disruptive technology platform and consumer demand for better access to test results without inconvenient appointments or high costs. Ashok Krishnamurthi, Managing Partner at GreatPoint Ventures, emphasized the company's strong leadership in healthcare, diagnostics, and consumer technology, positioning it to transform point-of-care testing. Subsequent funding included an oversubscribed Series C of over $105 million in February 2021, led by TYH Ventures, Glen Tullman of 7wireVentures, and Wittington Ventures, with participation from GreatPoint Ventures and DNS Capital, advancing FDA clearance and commercialization efforts. Total funding has since exceeded $200 million across multiple rounds. |
| Sep 2015 | Seed | - | $2M | - |
Who has invested in Truvian Sciences?
12 investors have backed Truvian Sciences across its funding rounds, including GreatPoint Ventures, DNS Capital, Tao Capital Partners, 7wire Ventures, Wittington Ventures and TYH Ventures.
Lead investors include GreatPoint Ventures, Wittington Ventures, 7wire Ventures and TYH Ventures.
Truvian Sciences Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 3 | Participant | Nov 2019 | ||
| 3 | Lead | Nov 2019 | ||
| 2 | Participant | Nov 2019 | ||
| 2 | Lead | Feb 2021 | ||
| 2 | Lead | Feb 2021 | ||
| 2 | Lead | Feb 2021 | ||
| 1 | Participant | Feb 2021 | ||
| 1 | Participant | Nov 2019 | ||
| 1 | Participant | Feb 2021 | ||
| 1 | Participant | Feb 2021 | ||
This data is available for Pro users. Sign up to see all 12 Truvian Sciences investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialTruvian Sciences Competitors
Truvian Sciences competitors include listed companies like Roche, Thermo Fisher Scientific, Danaher and Agilent, and private ones like ArsenalBio and EverlyWell.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $77B | $26B | $351B | 4.9x | ||
| Publicly listed | $45B | $11B | $243B | 6.0x | ||
| Publicly listed | $25B | $6.9B | $149B | 6.6x | ||
| Publicly listed | $6.9B | $1.8B | $44B | 6.2x | ||
| Private | - | - | $1.9B | - | ||
| Private | $100M | - | $1.3B | 13.0x |
Truvian Sciences Public Comps
Truvian Sciences is still privately-owned, but its public comps include Samsung, Johnson & Johnson, Roche, Thermo Fisher Scientific, Siemens, Abbott, Danaher, Intuitive Surgical, Medtronic and Stryker.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $243B | $67B | 4.4x | 2.4x | 15.8x | 4.4x | |||
| $94B | $40B | 7.2x | 6.8x | 17.0x | 18.3x | |||
| $77B | $26B | 5.0x | 4.9x | 14.6x | 12.4x | |||
| $45B | $11B | 6.3x | 6.0x | 26.8x | 23.6x | |||
| $91B | $15B | 3.0x | 2.9x | 18.1x | 15.7x | |||
| $44B | $12B | 4.6x | 4.2x | 17.4x | 15.8x | |||
| $25B | $6.9B | 7.0x | 6.6x | 24.8x | 21.1x | |||
| $10B | $3.6B | 13.0x | 11.6x | 36.6x | 25.7x | |||
This data is available for Pro users. Sign up to see all Truvian Sciences competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Truvian Sciences
| When was Truvian Sciences founded? | Truvian Sciences was founded in 2015. |
| Where is Truvian Sciences headquartered? | Truvian Sciences is headquartered in United States. |
| Is Truvian Sciences publicly listed? | No, Truvian Sciences is a private, VC-backed company. |
| How much funding has Truvian Sciences raised? | Truvian Sciences has raised $208M across 4 funding rounds. |
| What was Truvian Sciences' last funding round? | Truvian Sciences' last funding round was a $74M Series D in July 2024, led by GreatPoint Ventures and Wittington Ventures. |
| Who are Truvian Sciences' investors? | Truvian Sciences' investors include DNS Capital, GreatPoint Ventures, Tao Capital Partners, Wittington Ventures, 7wire Ventures, TYH Ventures, General Catalyst, Domain Associates, Synetro Group, Wasson Enterprise and 2 others. |
| Which companies are comparable to Truvian Sciences? | Companies comparable to Truvian Sciences include Roche, Thermo Fisher Scientific, Danaher, Agilent, ArsenalBio and EverlyWell. |
See companies similar to Truvian Sciences
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




